Kawasaki disease (KD), also known as cutaneous mucosal lymph node syndrome, is an acute self limiting vasculitis of unknown cause. The disease was first found in Japanese children in 1967 and its characteristic clinical features were described. The typical clinical symptoms of Kawasaki disease include fever ≥ 5 days, bilateral non suppurative conjunctivitis, rash, cervical lymphadenopathy and changes of skin and mucosa. These characteristics are still the main basis for the diagnosis of KD. However, the listed clinical features are not unique to KD, and other diseases can also have the above-mentioned clinical manifestations. Therefore, KD cannot be diagnosed only by clinical features. However, timely diagnosis and treatment is the key to reduce the incidence of related heart diseases. About 25% of untreated KD children develop coronary artery aneurysms (CAA). At present, KD is an important cause of acquired heart disease in children in the United States. For the treatment of KD, most studies recommend high-dose intravenous immunoglobulin (IVIG), which can significantly reduce the incidence of cardiac involvement. In recent years, with the continuous progress of relevant diagnosis and treatment technology, the diagnosis and treatment of KD has made great progress. This study reviews the relevant literature and briefly summarizes the clinical diagnosis and treatment of Kawasaki disease in children, in order to provide some reference for the clinical diagnosis and treatment of KD.

Liyan Zhao. Advances in clinical diagnosis and treatment of Kawasaki disease in children. Frontiers in Medical Science Research (2022) Vol. 4, Issue 7: 44-47. https://doi.org/10.25236/FMSR.2022.040707.

[1] Zhu F, Ang JY. 2021 Update on the Clinical Management and Diagnosis of Kawasaki Disease [J]. Curr Infect Dis Rep, 2021,23(3):3.

[2] Rohani P, Imanzadeh F, Sayyari A, et al. Persistent elevation of aspartate aminotransferase in a child after incomplete Kawasaki disease: a case report and literature review [J]. BMC Pediatr, 2020, 20(1):73.

[3] Aldemir-Kocabaş B, Kcal MM, Ramoğlu MG, et al. Recurrent Kawasaki disease in a child with retropharyngeal involvement: a case report and literature review [J]. Medicine (Baltimore), 2014,93(29):e139.

[4] Shahbaz FF, Martins RS, Umair A, et al. A Review of Coronaviruses Associated With Kawasaki Disease: Possible Implications for Pathogenesis of the Multisystem Inflammatory Syndrome Associated With COVID-19[J]. Clin Med Insights Pediatr, 2022, 16:11795565221075319.

[5] Yohannan TM. Heart Transplant, Kawasaki Disease, and Bone Marrow Transplant: Are There Consequences?[J]. Curr Atheroscler Rep, 2022,24(4):243-251.

[6] Evidence review for signs and symptoms predicting Kawasaki disease: Fever in under 5s: assessment and initial management: Evidence review A[M]. London:National Institute for Health and Care Excellence (NICE),2019.

[7] Scherler L, Haas NA, Tengler A, et al. Acute phase of Kawasaki disease: a review of national guideline recommendations[J]. Eur J Pediatr, 2022.

[8] Hu B. Effect of different doses of gamma globulin in the treatment of children kawasaki disease [J].  Chinese Health Standard Management, 202,13(06):117-120.  

[9] Liu Shuhua.  Application and clinical efficacy analysis of different doses of gamma globulin in the treatment of children with Kawasaki disease [J].  Gansu Science and Technology, 201,37(19):138-140.  

[10] ZHAO Jian, HUANG Min, XIE Lijian, et al.  Clinical analysis of combined glucocorticoids in initial treatment of kawasaki disease [J]. International journal of pediatrics, 2017, 44(09):642-645+649.  

[11] Hou Weiner.  Effects of different doses of glucocorticoid on ESR, CRP and NT-probNP in peripheral blood of kawasaki disease with non-responsive gamma globulin [J].  Journal of aerospace medicine, 2018,29(02):180-182.  

[12] Liu Gaiyan.  Clinical analysis of intravenous injection of gamma globulin combined with glucocorticoid in the treatment of gamma globulin non-responsive Kawasaki disease [J].  World latest medical information abstracts, 2018,18(84):116+118.  

[13] Du Zhongdong, ZHANG Weihua, Yang Xiaodong, et al.  Pediatric expert consensus on glucocorticoids in the treatment of Kawasaki disease [J]. Chin J Clin Pediatr, 202,24(03):225-231.  

[14] Li Fangfang, LI Chongwei.  Research progress of glucocorticoids in the initial treatment of kawasaki disease [J]. Medical review, 2020, 26(12):2396-2401.  

[15] Fu Qiang, Huang Huali, Li Aimin.  Effects of glucocorticoids on autonomic nervous function in children with kawasaki disease without intravenous gamma globulin sensitivity [J].  Chinese Journal of General Medicine, 201, 24(05):577-580.  

[16] Hua Xiaoxing, Li Jiezhen, Jiang Lianying.  Effect of hormone therapy in children with kawasaki disease [J]. Practical clinical medicine, 2020, 21(12):40-42+55. (in Chinese)  

[17] Shi Xiaoliang, TONG Xing.  Effect of hormone sequential therapy on children with kawasaki disease with non-responsive gamma globulin [J]. China Maternal and Child Health care, 201, 36(08):1785-1787.  

[18] Buda P, Friedman-Gruszczyńska J, Książyk J. Anti-inflammatory Treatment of Kawasaki Disease: Comparison of Current Guidelines and Perspectives [J]. Front Med (Lausanne), 2021,8:738850.

[19] Mitsuishi T, Miyata K, Ando A, et al. Characteristic nail lesions in Kawasaki disease: Case series and literature review [J]. J Dermatol, 2022,49(2):232-238.